Growth Stock Wire Investment Newsletter

 
Growth Stock Wire Investment Newsletter About Growth Stock Wire Frequently Asked Questions Growth Stock Wire Archives Contact Us Privacy Policy
Print Edition | Sponsored Link:
Congrats. Now Don't Forget to Book Your Profits...
By Rob Fannon
December 11, 2009

We nailed it.

Last Friday, I showed you a low-risk biotech trade setting up to deliver big gains in less than a week. Before we get to where the trade is today, let me back up...

The 51st annual meeting of the American Society of Hematology, commonly known as "ASH," wrapped up on Tuesday. It's one of the biggest cancer meetings of the year.

Biotechs use conferences like ASH to release important trial results, announce partnerships, and reveal new acquisitions. Of course, all of the above are stock price-moving events. Traders thrive on the short-term volatility.

The most anticipated news at this year's ASH was data from biotech player Celgene. The company unveiled Phase III results for its blockbuster drug, Revlimid, in newly diagnosed, early-stage multiple myeloma patients.

In short, Celgene's Revlimid numbers were a mixed bag. The drug helps patients ward off cancer after the first round of chemotherapy. But it failed to show a clear benefit when added to chemotherapy in the earliest stages of treatment. At $60,000 per year, doctors won't use the drug in early treatment without crystal-clear proof Revlimid is helping patients live longer.

To be fair, this Phase III trial is still ongoing. When the full results are ready in late 2010, Celgene may emerge the winner. But the market is an instant-gratification beast. Doubts about Revlimid sent Celgene's market cap down $1.5 billion this week.

We didn't know how Celgene's data would look. But we did know this: Regardless of the outcome, Celgene's stock would be on the move. To capture this volatility, we put on a "long straddle."

A long straddle involves the purchase of both a call and a put option at the same strike price. You win if the stock price moves a certain amount in either direction. You lose if it stays the same. So a long straddle is a perfect way to play volatility.

To play the Celgene results, I suggested buying the December $57.50 call and put options for $1.75 each – for an upfront cost of $3.50. As long as Celgene's stock moved above $61 ($57.50 plus $3.50) or below $54 ($57.50 minus $3.50), we'd win.

If you took my advice, congratulations. While your gains came up short of my triple-digit goal, we got a gift from the market. Here's how it worked out...

On Tuesday, Celgene shares opened at $53, dropping as low as $52.75 on Wednesday. That downward movement caused a spike in the put options. (They traded hands above $4.50 at one point.) Meanwhile, the calls fell to $0.25. So you could have sold both for a total of $4.75. That's $1.25 in profit on your $3.50 – a 35% gain.

 
Related Articles
A Low-Risk Double... No Matter Which Way the Stock Moves
This Could Be the Biggest Biotech Trade of 2010
 

For those traders who still hold the position, you have a chance to book a nice profit. As I write, Celgene shares are hovering around $53.70. The December $57.50 calls and puts can be sold for at least $4, a 15% gain. Not bad for a seven-day trade.

You have until next Friday, option-expiration day, to close out your position. But prices will drop as we get closer to that date. So if you haven't closed it out already, I suggest you do so now.

If you missed this trade, don't worry. We'll use more low-risk, high-reward trading strategies like the Celgene straddle to play biotech volatility in 2010.

Good investing,

Rob Fannon

World's greatest reporter Stossel debuts new show tonight
First news program dedicated exclusively to economic liberty and free markets...

This is why most Americans hate George Soros
Great speculator wants to give your money to other countries...

The euro is doomed
A default by Greece, or any of the other troubled European nations, could spell its end...


Intel surges... world's largest chipmaker hits a fresh 52-week high.
Big utility rally continues... Duke, Dominion, PG&E, and others make new highs.
Bond market signals inflation... long-term rates creep higher as short-term rates stay low, creating the biggest spread in 17 years.
Copper slides down 4.5% from 15-month high.
Last Change 52-Wk
S&P 500 1109.30 +1.45% +27.03%
Oil (USO) 40.29 +2.99% -12.75%
Gold (GLD) 111.63 +1.72% +52.29%
Silver (SLV) 18.01 +5.01% +92.41%
U.S. Dollar 75.37 +0.68% -13.15%
Euro
1.49
-0.70%
+17.54%
VIX 22.89 -2.01% -65.48%
HUI 475.53 +3.26% +155.07%
10-Year Yield 3.33% -0.10 -0.37

Advertisement

Company Sym Industry

IBM

IBM

computers

3M

MMM

conglomerate

MedcoHealth

MHS

pharma

Enbridge

ENB

pipelines

Marvell Tech

MRVL

semiconductors

Southwest Air

LUV

airlines

Enterprise GP

EPE

refining

Microchip Tech

MCHP

semiconductors

ONEOK

OKE

utilities

Canon

CAJ

cameras

Canadian Natl Rail

CNI

railroads

American Electric

AEP

electric utilities

Republic Services

RSG

garbage

Dollar General

DG

discount stores

AMD

AMD

semiconductors

Lam Research

LRCX

semiconductors

Kinder Morgan

KMR

pipelines

Merck

MRK

pharma

Boeing

BA

Big Defense

Duke Energy

DUK

utilities

Broadcom

BRCM

semiconductors

Xcel Energy

XEL

utilities

Enbridge Energy

EEP

pipelines

Affiliated Computer

ACS

tech services

Windstream

WIN

telecom

Terra Industries

TRA

fertilizer

Coca-Cola

KO

soft drinks

Comcast

CMCSA

cable TV

Dominion

D

utilities

PG & E

PCG

utilities

Agrium

AGU

fertilizer

DTE Energy

DTE

utilities

ONEOK Partners

OKS

pipelines

Edwards

EW

medical devices

Braskem

BAK

chemicals 

Intel

INTC

semiconductors

Altria

MO

cigarettes

TransCanada

TRP

utilities

Telmex

TII

telecom

CIGNA

CI

health insurance

Altera

ALTR

semiconductors

Wisconsin Energy

WEC

utilities

Celanese

CE

chemicals 

F5 Networks

FFIV

networks

Verizon

VZ

telecom 

Potash

POT

chemicals 

Enterprise

EPD

oil & gas drilling

Sempra Energy

SRE

utilities

Canadian Pacific

CP

railroads

Warner Chilcott

WCRX

pharma

CenterPoint

CNP

utilities

SCANA

SCG

utilities

Marvel Ent

MVL

movie production

Walt Disney

DIS

entertainment

DIRECTV

DTV

telecom

Allergan

AGN

pharma

Progress Energy

PGN

utilities

Clorox

CLX

bleach

Rockwell Auto

ROK

electrical equip

LAN Airlines

LFL

airlines

R.R. Donnelley

RRD

printing

Steel Dynamics

STLD

steel

Company Sym Industry

Pantry

PTRY

grocery stores

Delta Petroleum

DPTR

oil & gas drilling

Seahawk Drilling

HAWK

oil & gas drilling

Kingsway

KFS

insurance

The Government Is About to Destroy the Market
December 10, 2009

Commodity Q&A: Your Questions on the One Alternative That Works

December 9, 2009

To Make More Money, Ask Yourself This One Question

December 8, 2009

The Only Reliable "Cycle" in the Market

December 7, 2009

Weekend Edition: Jim Rogers is Not Selling Under Any Circumstances

December 5, 2009

Home | About GSW | FAQ | GSW Archive | Privacy Policy | Contact Us

Customer Service: 1-888-261-2693 – Copyright 2010 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202